Usefulness of Radium-223 in Patients with Bone Metastases

Nishant GuptaDepartment of Radiology, Columbia University Medical Center, New York, New York (Gupta)Correspondence[email protected]

, MD,

Arushi DevganDepartment of Radiology, University of Arkansas, Little Rock, Arkansas (Devgan)

, MBBS,

Itisha BansalDepartment of Anesthesiology, New York-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York (Bansal)

, MD,

Thomas D. OlsavskyDepartment of Nuclear Medicine, St. Vincent's Medical Center, Bridgeport, Connecticut (Olsavsky)

, MD,

Shuo LiDepartment of Radiology, Yale New Haven Health at Bridgeport Hospital, Bridgeport, Connecticut (Li, Abdelbaki)

, MD,

Ahmed AbdelbakiDepartment of Radiology, Yale New Haven Health at Bridgeport Hospital, Bridgeport, Connecticut (Li, Abdelbaki)

, MD &

Yogesh KumarColumbia University at Bassett Healthcare, Cooperstown, New York (Kumar).

, MD show all

Abstract

Castration-resistant prostate osseous metastases can be challenging to treat. There is a new era of clinical advancement with the Food and Drug Administration approval of radium-223 for use in these patients. Radium-223 is the only clinically used therapeutic radiopharmaceutical that emits alpha particles, making it extremely safe for therapeutic purposes for the patient as well as close contacts. This review discusses radium-223's mechanism of action, pharmacokinetics, indications, and safety profile, as well as findings of concluded clinical trials.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Usefulness of Radium-223 in Patients with Bone Metastases

Information for

Open access

Opportunities

Help and information

Usefulness of Radium-223 in Patients with Bone Metastases

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature